WO2011018246A3 - Controlled release paliperidone composition - Google Patents

Controlled release paliperidone composition Download PDF

Info

Publication number
WO2011018246A3
WO2011018246A3 PCT/EP2010/005211 EP2010005211W WO2011018246A3 WO 2011018246 A3 WO2011018246 A3 WO 2011018246A3 EP 2010005211 W EP2010005211 W EP 2010005211W WO 2011018246 A3 WO2011018246 A3 WO 2011018246A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
paliperidone
independently
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/EP2010/005211
Other languages
French (fr)
Other versions
WO2011018246A2 (en
Inventor
Korinde Annemarie Jansen
Original Assignee
Synthon B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon B.V. filed Critical Synthon B.V.
Publication of WO2011018246A2 publication Critical patent/WO2011018246A2/en
Publication of WO2011018246A3 publication Critical patent/WO2011018246A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Abstract

The present invention relates to A controlled-release pharmaceutical tablet, comprising: (a) an inner hydrogel tablet core comprising paliperidone or a pharmaceutically acceptable salt thereof and a pH-independently gelling polymer; and (b) an outer hydrogel layer surrounding said inner tablet core comprising a pH-independently gelling polymer; wherein said outer layer does not contain paliperidone or a pharmaceutically acceptable salt thereof, to a method of making such tablets and for use in medicine.
PCT/EP2010/005211 2009-08-13 2010-08-11 Controlled release paliperidone composition WO2011018246A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23355109P 2009-08-13 2009-08-13
US61/233,551 2009-08-13

Publications (2)

Publication Number Publication Date
WO2011018246A2 WO2011018246A2 (en) 2011-02-17
WO2011018246A3 true WO2011018246A3 (en) 2011-04-21

Family

ID=43569173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/005211 WO2011018246A2 (en) 2009-08-13 2010-08-11 Controlled release paliperidone composition

Country Status (1)

Country Link
WO (1) WO2011018246A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
CN110251475B (en) * 2019-07-25 2021-07-16 沈阳信康药物研究有限公司 Paliperidone tablet and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
WO2004010981A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
WO2009025859A1 (en) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation
WO2009109993A1 (en) * 2008-02-04 2009-09-11 Torrent Pharmaceuticals Ltd. Extended release dosage form of paliperidone
WO2010009900A1 (en) * 2008-07-25 2010-01-28 Krka, D.D. Novo Mesto Paliperidone composition comprising solid matrix particles
WO2010044097A2 (en) * 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
MX2007001563A (en) 2004-08-04 2008-03-05 Johnson & Johnson Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition.
WO2006085856A1 (en) 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20070190137A1 (en) 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
US20070166381A1 (en) 2006-01-06 2007-07-19 Iran Reyes Osmotic dosage form with controlled release and fast release aspects
JP2009524685A (en) 2006-08-14 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド Crystal form of 9-hydroxy-risperidone (paliperidone)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
WO2004010981A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
WO2009025859A1 (en) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation
WO2009109993A1 (en) * 2008-02-04 2009-09-11 Torrent Pharmaceuticals Ltd. Extended release dosage form of paliperidone
WO2010009900A1 (en) * 2008-07-25 2010-01-28 Krka, D.D. Novo Mesto Paliperidone composition comprising solid matrix particles
WO2010044097A2 (en) * 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same

Also Published As

Publication number Publication date
WO2011018246A2 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
WO2008146178A3 (en) A novel tablet dosage form
WO2011077451A3 (en) Controlled release pharmaceutical composition
WO2011115969A3 (en) Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form
MX2015011896A (en) Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration.
IL208832A (en) 3-aminocarbazole compounds, pharmaceutical compositions containing them, preparation methods thereof and use thereof in the production of drugs
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
WO2011101866A3 (en) Gastric retention formulation containing baclofen
MX354416B (en) Nalbuphine-based formulations and uses thereof.
IL215826A (en) Sustained release pharmaceutical composition, process for its preparation, its use for the manufacture of a medicament for the treatment of pain and a tablet comprising it
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010127205A3 (en) Fixed dose drug combination formulations
IN2015DN04161A (en)
WO2009149058A8 (en) Modified release niacin formulations
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2011131370A8 (en) Melt-granulated fingolimod
WO2012052834A3 (en) Multiple unit particulate system comprising metoprolol succinate
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
WO2011047837A3 (en) Melt-granulated cinacalcet
EP3648745A4 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
PH12016500693A1 (en) Slow-release solid oral compositions
WO2011018246A3 (en) Controlled release paliperidone composition
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
WO2011018185A3 (en) Pharmaceutical tablet comprising rosuvastatin calcium
WO2016161988A3 (en) Pharmaceutical composition containing spherical clopidogrel bisulphate crystalline form i, and preparation method for pharmaceutical composition
JP2015500812A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10776290

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10776290

Country of ref document: EP

Kind code of ref document: A2